Clear All
760 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9062 Daratumumab Hyaluronidase Darzalex Faspro 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Oct 1, 2020 Jan 1, 2021 No Longer Used
C9058 Pegfilgrastim-bmez Ziextenzo 0.5mg Ancillary Therapy immunomodulatorne Granulocyte Colony Stimulating Factor No 2019 Mar 31, 2020 Jul 1, 2020 No Longer Used
C9027 Pembrolizumab Keytruda 1 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2014 Jan 1, 2015 Dec 31, 2015 No Longer Used
C9025 Ramucirumab Cyramza 5 mg Immunotherapy Monoclonal Antibody VEGFR No 2014 Oct 1, 2014 Dec 31, 2015 No Longer Used
C9024 (Daunorubicin AND Cytarabine) Liposome Vyxeos 1mg/2.27mg Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog No 2017 In Use
C9021 Obinutuzumab Gazyva 10 mg Immunotherapy Monoclonal Antibody CD20 No 2013 Apr 4, 2014 Dec 31, 2014 No Longer Used
C9012 Arsenic Trioxide Trisenox unspecified Chemotherapy Miscellaneous Agent PML/RARa No 2000 Jan 1, 2001 Dec 31, 2001 No Longer Used
C9004 Gemtuzumab ozogamicin Mylotarg 5 mg Immunotherapy Drug Antibody Conjugate CD33 No 2000 Jan 1, 2004 Dec 31, 2005 No Longer Used
C1086 Temozolomide Temodar 5 mg Chemotherapy Alkylating Agent Tetrazine Yes 1999 Jan 1, 2010 In Use
BA Belzutifan Welireg 40mg Chemotherapy Miscellaneous Agent HIF-2 alpha Yes 2021 In Use
A9607 Lutetium Lu 177 vipivotide tetraxetan PLUVICTO 1 millicurie Radiopharmaceutical Radiopharmaceutical In Use
A9545 Tositumomab Bexxar, Iodine i-131 Tositumomab, therapeutic Per treatment dose Immunotherapy, Radiopharmaceutical Radioimmunotherapy CD20 No 2003 2014 Jan 1, 2006 In Use
A9534 Tositumomab Bexxar, Iodine i-131 Tositumomab, therapeutic per MC Immunotherapy, Radiopharmaceutical Radioimmunotherapy CD20 No 2003 2014 Jul 1, 2003 In Use
Capivasertib Truqap 160mg, 200mg Chemotherapy AKT Inhibitor AKT 1/2/3 Yes 2023 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
Repotrectinib Augtyro 40mg, 160mg Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Yes 2023 In Use
Vorasidenib Voranigo 10mg,40mg Chemotherapy IDH Inhibitor IDH1, IDH2 Yes 2024 In Use
Revumenib Revuforj 25mg, 110mg, 160mg Chemotherapy Enzyme Inhibitor KMT2A Yes 2024 In Use
Mobocertinib Exkivity 40mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2021 In Use
Adagrasib Krazati 200mg Immunotherapy RAS Inhibitor KrAS G12C Yes 2022 In Use
Fruquintinib Fruzaqla 1mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2023 In Use
Momelotinib Ojjaara Multiple Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2023 In Use
Pacritinib Vonjo 100mg Chemotherapy Tyrosine Kinase Inhibitor JAK2, FLT3 Yes 2022 In Use
Infigratinib Truseltiq Multiple Chemotherapy Tyrosine Kinase Inhibitor FGFR Yes 2021 In Use
Tovorafenib Ojemda 25mg, 100mg Chemotherapy Enzyme Inhibitor BRAF, CRAF Yes 2024 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.